Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas.
Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas.
复制标题
DOI:
10.1038/s41598-021-94592-9
复制
发表时间:
2021-07-22
影响因子:
4.6
通讯作者:
Suda T
中科院分区:
文献类型:
--
作者:
Akahori D;Inoue Y;Inui N;Karayama M;Yasui H;Hozumi H;Suzuki Y;Furuhashi K;Fujisawa T;Enomoto N;Nakamura Y;Suda T
Genotyping epidermal growth factor receptor (EGFR) is an essential process to indicate lung adenocarcinoma patients for the most appropriate treatment. Liquid biopsy using circulating tumor DNA (ctDNA) potentially complements the use of tumor tissue biopsy for identifying genotype-specific mutations in cancer cells. We assessed the performance of a high-fidelity sequencing method that uses molecular barcodes called the nonoverlapping integrated read sequencing system (NOIR-SS) for detecting EGFR L858R-mutated alleles in 33 advanced or recurrent patients with L858R mutation-positive lung adenocarcinoma revealed by matched tissue biopsy. We compared NOIR-SS with site-specific droplet digital PCR (ddPCR), which was taken as the reference, in terms of sensitivity and ability to quantify L858R variant allele fractions (VAFs). NOIR-SS and ddPCR had sensitivities of 87.9% (29/33) and 78.8% (26/33) for detecting L858R alleles, respectively. The VAFs measured by each assay were strongly correlated. Notably, one specimen was positive with a VAF of 30.12% for NOIR-SS but marginally positive with that of 0.05% for ddPCR because of a previously poorly recognized mechanism: two-base substitution-induced L858R (c.2573_2574delinsGA). These results indicate that NOIR-SS is a useful method for detecting ctDNA, potentially overcoming a limitation of ddPCR which highly depends on the binding ability of primers to specific targeting sequences.
登录
查看更多内容
DOI:
10.1093/annonc/mdt205
发表时间:
2013-09
期刊:
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子:
--
作者:
Dearden S;Stevens J;Wu YL;Blowers D
通讯作者:
Blowers D
DOI:
10.1158/1078-0432.ccr-17-0291
发表时间:
2017-09-15
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Janku F;Zhang S;Waters J;Liu L;Huang HJ;Subbiah V;Hong DS;Karp DD;Fu S;Cai X;Ramzanali NM;Madwani K;Cabrilo G;Andrews DL;Zhao Y;Javle M;Kopetz ES;Luthra R;Kim HJ;Gnerre S;Satya RV;Chuang HY;Kruglyak KM;Toung J;Zhao C;Shen R;Heymach JV;Meric-Bernstam F;Mills GB;Fan JB;Salathia NS
通讯作者:
Salathia NS
DOI:
10.1016/j.jtho.2018.03.035
发表时间:
2018-08
期刊:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子:
--
作者:
Lisberg A;Cummings A;Goldman JW;Bornazyan K;Reese N;Wang T;Coluzzi P;Ledezma B;Mendenhall M;Hunt J;Wolf B;Jones B;Madrigal J;Horton J;Spiegel M;Carroll J;Gukasyan J;Williams T;Sauer L;Wells C;Hardy A;Linares P;Lim C;Ma L;Adame C;Garon EB
通讯作者:
Garon EB
DOI:
10.1073/pnas.0507904102
发表时间:
2005-11-08
影响因子:
11.1
作者:
Diehl, F;Li, M;Vogelstein, B
通讯作者:
Vogelstein, B
影响因子:
3.7
作者:
Kukita Y;Ohkawa K;Takada R;Uehara H;Katayama K;Kato K
通讯作者:
Kato K